1. Global, regional, and national burden of calcific aortic valve and degenerative mitral valve diseases, 1990-2017
- Author
-
Irina Filip, Félix Carvalho, Dhaval Kolte, Jalal Arabloo, Muthiah Vaduganathan, Abdur Rahman Khan, Olayinka Stephen Ilesanmi, Trang Huyen Nguyen, Alaa Alashi, Ahmad Daryani, Ali Bijani, Adnan Kisa, Molly R Nixon, Charles D.A. Wolfe, Navid Manafi, Andre Pascal Kengne, Leonardo Roever, Tommi Vasankari, Andre Rodrigues Duraes, Adam E. Berman, Samer Hamidi, Seyed Sina Naghibi Irvani, Shanti Patel, Ruxandra Irina Negoi, Sezer Kisa, Celine M. Barthelemy, Aziz Rezapour, Huong Lan Thi Nguyen, Catherine O. Johnson, Ali H. Mokdad, Anas M. Saad, Berhe Etsay Tesfay, Mohsen Afarideh, Simon I. Hay, Erkin M. Mirrakhimov, Amir Manafi, Rufus A. Adedoyin, Eduarda Fernandes, Simon Yadgir, Catherine M Otto, Vahid Alipour, Irfan Ullah, George A. Mensah, Talha Farid, Bach Xuan Tran, Alireza Esteghamati, Farshad Farzadfar, Mohamed M. Gad, Oladimeji Adebayo, Mikk Jürisson, Amir Kasaeian, Victor Aboyans, Gregory A. Roth, Catherine P. Benziger, Naohiro Yonemoto, Amir Radfar, Wasiq Faraz Rawasia, David Laith Rawaf, Juan Jesus Carrero, Thomas Pilgrim, Samad Azari, Karen Sliwa, Seyedmohammad Saadatagah, Yousef Mohammad, Salman Rawaf, Fares Alahdab, and Subramanian Senthilkumaran
- Subjects
Male ,Aortic valve ,Burden of disease ,mitral valve ,medicine.medical_specialty ,Time Factors ,Aortic Valve Insufficiency ,030204 cardiovascular system & hematology ,Global Health ,Risk Assessment ,heart valve diseases ,1117 Public Health and Health Services ,03 medical and health sciences ,Age Distribution ,0302 clinical medicine ,Cost of Illness ,Risk Factors ,Physiology (medical) ,Mitral valve ,Internal medicine ,Prevalence ,Humans ,Medicine ,030212 general & internal medicine ,Global Burden of Disease Study 2017 Nonrheumatic Valve Disease Collaborators ,Healthcare Disparities ,610 Medicine & health ,1102 Cardiorespiratory Medicine and Haematology ,Mitral Valve Prolapse ,global burden of disease ,business.industry ,Mitral valve diseases ,Calcinosis ,Mitral Valve Insufficiency ,1103 Clinical Sciences ,Aortic Valve Stenosis ,Health Status Disparities ,aortic valve ,medicine.anatomical_structure ,Cardiovascular System & Hematology ,Quality of Life ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background: Nonrheumatic valvular diseases are common; however, no studies have estimated their global or national burden. As part of the Global Burden of Disease Study 2017, mortality, prevalence, and disability-adjusted life-years (DALYs) for calcific aortic valve disease (CAVD), degenerative mitral valve disease, and other nonrheumatic valvular diseases were estimated for 195 countries and territories from 1990 to 2017. Methods: Vital registration data, epidemiologic survey data, and administrative hospital data were used to estimate disease burden using the Global Burden of Disease Study modeling framework, which ensures comparability across locations. Geospatial statistical methods were used to estimate disease for all countries, because data on nonrheumatic valvular diseases are extremely limited for some regions of the world, such as Sub-Saharan Africa and South Asia. Results accounted for estimated level of disease severity as well as the estimated availability of valve repair or replacement procedures. DALYs and other measures of health-related burden were generated for both sexes and each 5-year age group, location, and year from 1990 to 2017. Results: Globally, CAVD and degenerative mitral valve disease caused 102 700 (95% uncertainty interval [UI], 82 700–107 900) and 35 700 (95% UI, 30 500–42 500) deaths, and 12.6 million (95% UI, 11.4 million–13.8 million) and 18.1 million (95% UI, 17.6 million–18.6 million) prevalent cases existed in 2017, respectively. A total of 2.5 million (95% UI, 2.3 million–2.8 million) DALYs were estimated as caused by nonrheumatic valvular diseases globally, representing 0.10% (95% UI, 0.09%–0.11%) of total lost health from all diseases in 2017. The number of DALYs increased for CAVD and degenerative mitral valve disease between 1990 and 2017 by 101% (95% UI, 79%–117%) and 35% (95% UI, 23%–47%), respectively. There is significant geographic variation in the prevalence, mortality rate, and overall burden of these diseases, with highest age-standardized DALY rates of CAVD estimated for high-income countries. Conclusions: These global and national estimates demonstrate that CAVD and degenerative mitral valve disease are important causes of disease burden among older adults. Efforts to clarify modifiable risk factors and improve access to valve interventions are necessary if progress is to be made toward reducing, and eventually eliminating, the burden of these highly treatable diseases.
- Published
- 2020